The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 333:458-460 August 17, 1995 Number 7
NextNext

Angiotensin-Converting–Enzyme Genotype and Ischemic Heart Disease

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-Related Article
 by Lindpaintner, K.
-PubMed Citation
To the Editor: Lindpaintner et al. (March 16 issue)1 conclude that the presence of the angiotensin-converting–enzyme (ACE) genotype does not alter the risk of myocardial infarction or coronary artery disease. We think that the results of their study may have been influenced by the use of ACE inhibitors, which reduce the level of ACE in the blood.2 During the period from 1982 to 1992, when ACE inhibitors were widely used to treat hypertension, 28.1 percent of the case patients and 16.7 percent of the controls had hypertension.

The use of ACE inhibitors would tend to obscure the effect . . . [Full Text of this Article]

References


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.